Micro and nanoscale technologies in oral drug delivery

Samad Ahadian; Joel A Finbloom; Mohammad Mofidfar; Sibel Emir Diltemiz; Fatemeh Nasrollahi; Elham Davoodi; Vahid Hosseini; Ioanna Mylonaki; Sivakoti Sangabathuni; Hossein Montazerian; Kirsten Fetah; Rohollah Nasiri; Mehmet Remzi Dokmeci; Molly M Stevens; Tejal A Desai; Ali Khademhosseini

doi:10.1016/j.addr.2020.07.012

Micro and nanoscale technologies in oral drug delivery

Adv Drug Deliv Rev. 2020:157:37-62. doi: 10.1016/j.addr.2020.07.012. Epub 2020 Jul 22.

Authors

Samad Ahadian¹, Joel A Finbloom², Mohammad Mofidfar³, Sibel Emir Diltemiz⁴, Fatemeh Nasrollahi⁵, Elham Davoodi⁶, Vahid Hosseini¹, Ioanna Mylonaki⁷, Sivakoti Sangabathuni⁵, Hossein Montazerian⁵, Kirsten Fetah⁵, Rohollah Nasiri⁸, Mehmet Remzi Dokmeci⁹, Molly M Stevens¹⁰, Tejal A Desai¹¹, Ali Khademhosseini¹²

Affiliations

¹ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA 90024, USA.
² Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, USA.
³ Department of Biomedical Engineering, University of Southern California, Los Angeles, CA 90089, USA.
⁴ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Department of Chemistry, Faculty of Science, Eskisehir Technical University, Eskisehir 26470, Turkey.
⁵ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA.
⁶ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Department of Mechanical and Mechatronics Engineering, University of Waterloo, Waterloo, ON N2L 3G1, Canada.
⁷ Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London SW7 2AZ, UK.
⁸ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Department of Mechanical Engineering, Sharif University of Technology, Tehran 11365-11155, Iran.
⁹ Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA 90024, USA; Department of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA 90095, USA.
¹⁰ Department of Materials, Department of Bioengineering, Institute of Biomedical Engineering, Imperial College London, London SW7 2AZ, UK. Electronic address: m.stevens@imperial.ac.uk.
¹¹ Department of Bioengineering and Therapeutic Sciences, University of California, San Francisco, CA 94143, USA. Electronic address: tejal.desai@ucsf.edu.
¹² Department of Bioengineering, University of California-Los Angeles, Los Angeles, CA 90095, USA; Center for Minimally Invasive Therapeutics (C-MIT), University of California-Los Angeles, Los Angeles, CA 90095, USA; Terasaki Institute for Biomedical Innovation (TIBI), Los Angeles, CA 90024, USA; Department of Radiological Sciences, University of California-Los Angeles, Los Angeles, CA 90095, USA; Department of Chemical and Biomolecular Engineering, University of California-Los Angeles, Los Angeles, CA 90095, USA. Electronic address: khademh@terasaki.org.

Abstract

Oral administration is a pillar of the pharmaceutical industry and yet it remains challenging to administer hydrophilic therapeutics by the oral route. Smart and controlled oral drug delivery could bypass the physiological barriers that limit the oral delivery of these therapeutics. Micro- and nanoscale technologies, with an unprecedented ability to create, control, and measure micro- or nanoenvironments, have found tremendous applications in biology and medicine. In particular, significant advances have been made in using these technologies for oral drug delivery. In this review, we briefly describe biological barriers to oral drug delivery and micro and nanoscale fabrication technologies. Micro and nanoscale drug carriers fabricated using these technologies, including bioadhesives, microparticles, micropatches, and nanoparticles, are described. Other applications of micro and nanoscale technologies are discussed, including fabrication of devices and tissue engineering models to precisely control or assess oral drug delivery in vivo and in vitro, respectively. Strategies to advance translation of micro and nanotechnologies into clinical trials for oral drug delivery are mentioned. Finally, challenges and future prospects on further integration of micro and nanoscale technologies with oral drug delivery systems are highlighted.

Keywords: Drug delivery devices; Micro and nanocarriers; Micro and nanoscale technologies; Oral drug delivery; Tissue models.

Publication types

Research Support, Non-U.S. Gov't
Review

MeSH terms

Administration, Oral
Animals
Drug Carriers / chemistry
Drug Delivery Systems*
Humans
Hydrophobic and Hydrophilic Interactions
Microspheres*
Microtechnology / methods
Nanoparticles*
Nanotechnology / methods
Pharmaceutical Preparations / administration & dosage
Pharmaceutical Preparations / chemistry

Substances

Drug Carriers
Pharmaceutical Preparations

Abstract

Publication types

MeSH terms

Substances

Grants and funding